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Aim
Childhood chronic myeloid leukemia (CML) is rare
myeloproliferative disorder, and diagnosed mostly in
adult, representing for 10% of all CML, and accounts for
up to 2-3% of all childhood leukemia. Tyrosine kinase
inhibitor (TKI), mostly Imatinib mesylate, is now used
in the frontline standard treatment of CML in chronic
phase. The aim of this study is to investigate the growth
effect of TKI treatment in childhood CML.
Methods
This retrospective study consisted of 20 pediatric CML
patients (13 males and 7 females) received TKI treatment
at Seoul and Yeouido St. Mary hospital from January
2001 to January 2014. Patients with chronic-phase CML,
received TKI treatment for more than 6 months were
included. Height and weight data were obtained from the
patient’s medical records. The differences (Δ) of height
and weight standard deviation scores (SDS) at before and
after treatment were calculated and associations of fac-
tors that influence the growth were analyzed.
Result
Seventeen patients (85.0%) had reduction in height SDS
was observed. Mean age at the start of TKI was 10 years,
and median follow-up was 53 months. When the mean
levels of Δ height and weight SDS were analyzed, we
observed significant reduction in height SDS (mean±SE,
-0.35±0.33, P=0.000), but not in weight SDS (mean±SE,
-0.04±0.54, P=0.723). Growth deceleration was seen pre-
dominantly in patients who started TKI at a prepubertal
age compared with those who started at pubertal age or
started at prepubertal age but enter puberty on treatment
(mean±SE, -0.59 ±0.32 vs. -0.21±0.28, P=0.015). But no
significant difference of height SDS were observed
between two group depend on the TKI type. After
adjusting for type of puberty, significant linear correlations
with the reduction of height SDS after treatment was
found for age at onset treatment (r2=0.381, P=0.005).
Conclusion
After received TKI treatment in childhood CML patients,
a significant number of patients experience growth decel-
eration. Initiation of TKI treatment in prepubertal age
and age of begin treatment are associated with growth
impairment. Continuous follow-up and monitoring
growth after received TKI treatment in childhood CML
is important for improving quality of life.
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